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Abstract
Background: Fluorescence-enhancing microarray on plasmonic gold film is an attractive alternative to traditional
enzyme-linked immunosorbent assay (ELISA) for cytokine detection because of the increased sensitivity. The assay
chemistry is similar to an ELISA sandwich assay, but owing to the gold substrate, cytokine measurements are 10 to
100 times more sensitive and can be multiplexed. Plasmonic protein microarrays are, as other immunoassays,
affected by the presence of heterophilic antibodies and rheumatoid factor may lead to analytical errors with serious
implications for patient care. Here, we present a plasmonic gold substrate protein microarray for high-sensitivity
detection of cytokines with simultaneous assessment of rheumatoid factor interference on a single chip.
Results: Paired serum and synovial fluid samples from patients with rheumatoid arthritis (n = 18), osteoarthritis (n = 9)
or healthy controls (n = 10) were arrayed on near-infrared fluorescence enhancing plasmonic gold chips spotted with
cytokine-specific capture antibody and isotype control antibody. Possible rheumatoid factor interference was visualised
by a non-specific signal from the isotype control antibody, and pre-treatment of samples with heat-aggregated animal
IgG eliminated this background contamination. The platform was optimised using the cytokine IL-20. The protein
microarray platform allowed for the detection of human IL-20 at levels <1 pg/ml with reliable IL-20 quantification over
a 5-log dynamic range. Samples for which rheumatoid factor caused artefacts were identified and a method for
eliminating rheumatoid factor interference was developed and validated. IL-20 protein levels were significantly higher
in synovial fluid samples from patients with rheumatoid arthritis compared to osteoarthritis (p < 0.001), while serum
levels of IL-20 did not differ between patients with rheumatoid arthritis, osteoarthritis or healthy controls.
Conclusion: Using novel plasmonic gold chips, we developed a highly sensitive and accurate assay platform to detect
lowly expressed cytokines in biological fluids, allowing for the elimination of rheumatoid factor interference in as little
as 5 μl sample volume. The detection limit was below 1 pg/ml for IL-20 and linearity was achieved over a 5-log
dynamic range. This technology is highly advantageous for cytokines where sensitivity or sample volume is critical or
where assessment of rheumatoid factor interference needs addressed and eliminated.
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Background
Cytokines are low molecular weight proteins that exert
pleiotropic effects on cells involved in the immune and
acute phase responses. Because cytokines are crucially in-
volved in many biological processes such as hematopoiesis,
immunity, tumour genesis, haemostasis, vascularization
and repair of connective tissues, deregulation of cytokines
is implicated in the pathophysiology of a variety of human
diseases and may be used to refine diagnosis, measure the
progress of diseases, or predict and monitor the effects of
treatment [1]. Cytokine measurements using enzyme-
linked immunosorbent assay (ELISA), the current
standard procedure for protein quantification [2], is
often limited by the requirement of high sample vol-
ume (at least 50 μL), narrow dynamic range and low
throughput due to the analysis of a single analyte per
sample [3]. Compared with ELISA, protein microarray
technology on fluorescence-enhancing plasmonic gold
films recently described by Tabakman et al. [4] pro-
vides improved sensitivity and a broader dynamic range
while allowing for high-throughput analysis of multiple
determinants within a single sample [5–7].
We wanted to optimise this platform to work on cyto-
kines that are lowly expressed. We further wanted to
apply the technology on biological fluids from patients
with rheumatoid arthritis (RA) where samples are often
scarce in volume and may be compromised by the pres-
ence of heterophilic antibodies. We chose IL-20 as a
model cytokine due its widely described role in the
pathogenesis of several autoimmune diseases, including
psoriasis and RA [8]. IL-20 is up-regulated in psoriatic
skin [9], whereas in RA patients, it is expressed in syn-
ovial fibroblasts, mononuclear cells and neutrophil gran-
ulocytes of the synovial membrane [10]. No evidence
supports a role for IL-20 in the systemic immune
response, suggesting that IL-20 acts at local sites of
inflammation in RA patients. Finally, IL-20 is involved
in tumour growth and metastasis and represents a
promising target in the treatment of breast, bladder and
lung cancers [11–13].
IL-20 protein levels in human biological fluids report-
edly range from 60 pg/ml to 1650 ng/ml [10, 14, 15].
For ELISA measurements, multiple sample dilutions are
required to cover this range, making reliable measure-
ments of serum/plasma and synovial fluid (SF) IL-20
challenging. Heterophilic antibodies, including Rheuma-
toid Factor (RF), further compromise data reliability, as
RF causes falsely increased or false positive results when
the cytokine is detected using traditional immunoassays,
e.g. ELISA, or bead based assays [16]. RF mainly inter-
feres with the measurement of cytokines by cross-
linking capture and detection antibodies [17]. RF has a
prevalence of up to 80 % in RA patients and 15 % in
healthy individuals [17, 18], thus there is a tremendous
need for novel sensitive assays that can assess and elim-
inate potential RF interference while having a broad
detection range.
Here, we show that by exploiting the near-infrared
physical fluorescence enhancement provided by a gold
film, plasmonic protein microarrays can detect cytokines
at sensitivities <1 pg/ml while covering a 5-log dynamic
range. On the same chip, RF interference was assessed
and false positive results caused by RF were eliminated.
The sample volume required was low (<5 μl), providing
major advantages when limited amounts of biological
materials are available.
Results
Detection of IL-20 protein levels using plasmonic gold
substrates
Highly similar standard curves were obtained from re-
combinant human (rh)-IL-20 expressed in E.Coli (pro-
duced by Novo Nordisk A/S or by R&D Systems) or
HEK-293 (produced by Novo Nordisk A/S) (Fig. 1a),
suggesting that post-translational modifications do not
interfere with detection of IL-20. Thus, IL-20 levels were
determined based on E.Coli-expressed rh-IL-20 (Novo
Nordisk A/S). Levels of IL-20 in the subject samples
ranged from 11–650 pg/ml.
Detection of IL-20 showed linearity over a 5-log dy-
namic range covering 2–20,000 pg/ml (r2 > 0.99) (Fig. 1a),
allowing for accurate cytokine quantification without the
need for multiple dilutions. Limit of detection (LOD)
was 0.2 pg/ml. Lower limit of quantification (LLOQ)
was 2 pg/ml, while the accuracy of the back-calculated
calibrator concentration was 91 % (87-95 %) and preci-
sion (coefficient of variation, CV%) was <20 %. Similar
sensitivities and dynamic ranges were obtained for other
cytokines; IL-6, TNFα, IL-1β and IL-10 (data not
shown). Spike-in recovery measurements were per-
formed in serum samples from three healthy controls
(HC) and were 93 % (72-113 %), which is within the
technical specification range of 70-130 % [2].
Elimination of RF interference
Spike-in recovery of cytokines in serum samples from RA
patients were affected by the presence of RF (data not
shown), highlighting the need for an estimate of RF inter-
ference and a protocol for eliminating the erroneous sig-
nal amplification. Regardless of whether anti-IL-20 or
isotype control was used as capture antibody, the fluores-
cence signals were similar for two RA serum samples
(Fig. 1b), indicating that RF interfered with IL-20 detec-
tion resulting in false positive signals. Pre-treatment of
samples with a mix of animal IgGs that were previously
heat aggregated, eliminated the RF interference (Fig. 1b).
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Levels of IL-20 in serum and synovial fluid of RA patients
IL-20 levels in SF were significantly higher (p < 0.001) in
RA patients (60 pg/ml, 24–445 pg/ml) than in patients
with osteoarthritis (OA) (32 pg/ml, 11–55 pg/ml)
(Fig. 2a). However, IL-20 levels in serum were compar-
able for RA (89 pg/ml, 45–643 pg/ml), OA (66 pg/ml,
30–105 pg/ml), or HC (71 pg/ml, 40–80 pg/ml) (Fig. 2b).
Pairwise comparison showed that the serum levels of IL-
20 were higher than the corresponding SF levels in OA
patients (p = 0.0078), while this was not the case in RA
patients (p = 0.167; Fig. 2c).
Discussion
RF interference in immuno-assays is a significant source
of uncertainty in medical testing and may cause mislead-
ing interpretation of the results for RA patients [19]. So
far, detection of RF interference has required measure-
ment of the same sample before and after addition of a
blocking agent [20] or following sample pre-treatment in
non-immune serum [21]. However these tests require a
large sample volume (up to 400 μl) [19], and may be in-
conclusive or require re-collection of sample material.
This study provides a novel protein microarray platform
based on plasmonic gold films that reliably detects cyto-
kines and assess for RF interference in 5 μl sample
volume.
This study focused on IL-20 due to its pro-inflammatory
role in autoimmune diseases and because this cytokine
requires a high-sensitivity assay for detection in SF where
limited sample material is available. However, the technol-
ogy can be applied to other cytokines provided that good
capture and detection antibody pairs can be obtained. We
have further optimised the assay for IL-6, TNFα, IL-1β and
IL-10.
IL-20 levels in SF have been measured using ELISA
[10, 22]. However data reliability needs to be confirmed
by negating an effect of RF [16], as traditional immuno-
assays produce high background noise if RF is present
[4]. By analysing serum and SF samples in arrays spotted
both with anti-IL-20 antibody and isotype control anti-
body, we could assess for false positive measurements
and show the successful elimination of RF interference.
The use of plasmonic gold substrates provided fluores-
cence enhancement, lowering the LOD to 0.2 pg/ml, a
level ~100 times lower than a traditional ELISA kit
(Human IL-20 Quantikine ELISA Kit, R&D systems,
LOD is ~20 pg/ml). Plasmonic gold chips also sup-
ported a wider dynamic range covering linear IL-20
detection over a 5-log dynamic range (2–2000 pg/ml,
r2 > 0.99) and inter and intra-runs CV of <20 %.
Similarly to data by Hsu et al. [10], we showed that IL-
20 levels were significantly higher in SF samples from
patients with RA compared to OA (p < 0.001). Our find-
ings were in contrast with those of Scrivo et al. [22], who
reported increased IL-20 levels in serum of RA compared
to OA and HC. Of note, the subjects included in the latter
study are not comparable to ours in terms of number and
clinical features. Moreover, RF interference was not
assessed in the paper by Scrivo et al. The IL-20 increase in
SF of RA patients rather than in the circulation supported
a role for IL-20 at the site of inflammation rather than in
the systemic immune response.
Fig 1 IL-20 quantification using plasmonic gold substrates. a)
IL-20 standard curves obtained using rh-IL-20 expressed in E.Coli
(produced by Novo Nordisk A/S (), or R&D Systems ()) or in
HEK-293 (Novo Nordisk A/S ()). rh-IL-20 was diluted in 5 % BSA in
PBS. Median ± SD fluorescence intensities are shown. Lower limit
of quantification (LLOQ) is indicated by the vertical dotted line.
b) Fluorescence intensities for IL-20 and isotype control capture
antibodies before and after pre-incubation with a mix of animal
IgGs. Serum (black) and synovial fluid (white) mean IL-20 levels ±
SD for two donors are shown. Representative maps (inserts)
shown for one donor
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Although traditional ELISA remains the method of
choice for cytokine detection in clinical laboratories, the
presence of RF will lead to analytical errors with serious
implications for patient care [23]. We show that artefacts
caused by RF assay interference can be eliminated by a
simple sample pre-treatment using heat-aggregated ani-
mal IgG. RF elimination can be done without affecting
assay sensitivity or cytokine detection. This platform was
validated using serum and SF samples from patients with
RA, OA and HC. Our protein microarrays on plasmonic
gold substrates can be deployed to assess and eliminate
RF interference to finally obtain reliable cytokine data
for use in the clinic and in research to increase quality
of patient care.
Conclusions
This study showed that plasmonic protein microarrays on
gold film substrate allowed for sensitive and reliable cyto-
kine quantification in biological fluids in 5 μl sample vol-
ume. On the same chip, rheumatoid factor interference
can be assessed and eliminated without requirement of
extra sample material or additional immunoassays. Hence,
this technology can be applied to reliably detect lowly
expressed cytokines in different biological sources even if
limited amounts of biological materials are available.
Methods
Clinical characteristics of patient groups
Samples from HC (n = 10, 5 female, 5 men) were from
BioreclamationIVT (West Sussex, UK), while samples
from patients with RA (n = 18, 12 female, 6 men) and
OA (n = 9, 6 female, 3 men) were from DVBiologics
(Costa Mesa, CA, USA). Mean age (±SD) for both RA
and OA groups was 65 (±13). Of the 18 RA patients, 17
were RF positive (mean titer ± SD; 26 ± 12). All RA pa-
tients were CRP positive (mean ± SD; 11 ± 5 mg/dl). Dis-
ease Activity Score in 28 Joints was >2.6 for all RA
patients indicating no remission cases. Validation of the
RF removal protocol was performed on 3 additional RA
samples (DVBiologics).
Written informed consent was obtained for all sub-
jects according to the Declaration of Helsinki and the
General Assembly Revision of 2008. The study has been
approved by the Ethics Committee of Copenhagen and
Frederiksberg.
Fig 2 IL-20 levels in synovial fluid and serum samples. a) IL-20 levels are higher in synovial fluid samples from patients with RA compared with
OA (p < 0.001). Each dot represents the average concentration for 1 patient based on 3 independent experiments, median and interquartile range
is shown. b) IL-20 levels in serum samples from RA, OA and HC. Data are represented as in (a). c) IL-20 levels in matched serum and
synovial fluid samples from OA and RA patients. Data are represented as in (a). IL-20 serum levels in OA patients were higher than
matched SF levels (p = 0.008)
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Protein array reagents
The following reagents were from Sigma–Aldrich (St.
Louis, MO, USA); 16-mercaptohexadecanoic acid, cys-
teamine, 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide, succinic anhydride and N-hydroxysuccinimide.
Triethylamine, dimethylformamide and bovine serum
albumin (BSA) were from Fisher Scientific (Pittsburgh,
PA, USA). Six-armed-poly(ethyleneglycol)–amine was
from SunBio (South Korea). PBS (Cat#70011-036) and
Tween-20 were from Life Technologies (Grand Island,
NY, USA).
Sandwich antibody pairs for IL-20 were produced by
Novo Nordisk A/S. Capture anti-IL-20 antibody was of the
IgG1 isotype. Unspecific binding was assessed using a IgG1
isotype control from R&D Systems (MAB002, Minneapolis,
MN, USA). IRDye-800 streptavidin conjugate was from
LiCor Biosciences (Lincoln, NE, USA). Mouse, goat and
bovine IgG were from Jackson ImmunoResearch (West
Grove, PA, USA).
Purified cytokine antigen standards and sandwich anti-
body pairs for IL-1β (MAB601, BAF201), IL-10 (MAB2172,
BAF217), IL-6 (MAB206, BAF206), and TNFα (MAB610,
BAF210) were purchased from R&D systems. All capture
antibodies were of the IgG1 isotype.
rh-IL-20 protein standards
Rh-IL-20 derived from E.Coli cells was purchased from
R&D systems (Cat#1102-IL-025) or produced at Novo
Nordisk A/S. Rh-IL-20 produced in HEK-293 cells was
from Novo Nordisk A/S. The activity of E.coli expressed
Met-IL-20 and HEK-293 expressed IL-20 was determined
by a IL-20R1/IL-20R2 Reporter Gene Assay (STAT-Luc)
showing EC50 of 896 and 819 pg/ml, respectively (data not
shown). The protein standards were diluted from 1 nM to
10 fM (17600–0.176 pg/ml) using 10-fold dilution steps in
5 % BSA in PBS.
IL-20 assay
Chemically modified plasmonic gold slides were pre-
pared as described [5]. Capture antibody or isotype
control antibody (3 μM in PBS + 1 % glycerol) were
printed in triplicate spots using Bio-Rad VersArray
Chipwriter and solid pins (Arrayit, USA) at 25 °C and
60 % humidity, resulting in microarray feature diame-
ters of ~400 μm. Slides were blocked overnight at 4 °C
in 5 % BSA in PBS. Samples (5 μl) were diluted 4-fold
in PBS and applied to each micro-well and incubated
for 4 h at RT. Slides were washed twice in 0.5 %
Tween-20 in PBS, once with PBS, and 5 nM human
biotinylated polyclonal antibody in 10 % BSA in PBS
was incubated over each micro-well for 1 h at RT.
Slides were washed as before and 2 nM IR800 conju-
gated streptavidin in 10 % BSA in PBS solution added
to the slides for 1 h at RT. After another wash, slides
were rapidly immersed in deionized water and dried
with compressed air.
Fluorescence measurement and data analysis
Slides were scanned using Odyssey scanner (Li-cor Bio-
sciences) as described [5]. Fluorescence intensities were
background-subtracted using the global background
subtraction method (GenePixPro V6), before calculat-
ing the median pixel intensities for features printed in
triplicates. Standard curves were obtained using 5-
parameter logistic curve. Limit of detection (LOD) was
defined as the concentration at three standard devia-
tions above the mean fluorescence of the blank. Lower
limit of quantification (LLOQ) was defined as the low-
est concentration at which the recovery of each calibra-
tor was within 70-130 % and the inter-run coefficients
of variation (CV) was <20 % [24]. The assay range was
defined as the concentration range in which the cyto-
kine measurements were linear (r2 > 0.99), inter and
intra-run CV was 20 %, respectively, and spike recover-
ies between 70-130 %. All cytokine measurements are
reported as median and range.
Statistical analysis was performed using GraphPad Prism
V.6 by applying a Mann–Whitney test. Wilcoxon matched-
pairs test was used to compare IL-20 levels in matched
serum and synovial fluid of each subject. P-values <0.05
were considered statistically significant.
Spike recoveries
Serum samples from three of the HCs were spiked with
20 or 2000 pg/ml of rh-IL-20 (produced in E.Coli by
Novo Nordisk A/S). Spike recoveries were obtained by
subtracting the observed concentration of the un-spiked
sample (observed un-spiked) from the observed concen-
tration of the added sample (observed spiked), and
divided by the known concentration of the spiked sam-
ple (expected spiked).
Removal of RF interference
By using an isotype control capture antibody, non-specific
signal due to RF can be identified [20, 21]. To remove RF
from biological samples showing RF-interference, we
applied a modified protocol of Kragstrup et al. [20], where
samples were diluted in an assay diluent containing a mix
of animal IgG (mouse, bovine and goat, each at 50 μg/ml
in PBS) previously heat-aggregated at 60 °C for 30 min.
Serum samples were diluted 4-fold in the assay diluent
containing animal IgG and incubated 30 min at RT. Sam-
ples were added to the gold slides and IL-20 detection
performed as described above. Cytokine measurements
were unaffected by addition of animal IgGs to serum
samples, as spike-in recoveries for samples with and with-
out animal IgG-treatment (n = 3, RA donors) were within
the accepted range of 70–130 % (IL-6, 99 % (94–103 %);
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IL-1β 93 % (92–95 %); TNFα, 98 % (84–112 %) and IL-10,
88 % (86–89 %).
For the analysis of RA, OA and HC samples, RF inter-
ference assessment was performed and interference iden-
tified for two RA samples for which the RF elimination
protocol was applied.
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